Randomized, Multicenter, Double-Blind Study of the Safety and Efficacy of 1%D-3-Hydroxybutyrate eye drops for Dry Eye Disease

Tetsuya Kawakita, Miki Uchino, Kazumi Fukagawa, Kenichi Yoshino, Seika Shimazaki, Ikuko Toda, Mari Tanaka, Hiroyuki Arai, Keiko Sakatani, Seiichiro Hata, Takashi Okano, Kazuo Tsubota

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In a previous study, we demonstrated that topical D-beta-hydroxybutyrate ameliorates corneal epithelial erosion and superficial punctate keratopathy in a rat model of dry eye disease. In the current investigation, we performed a prospective, randomized, multicentre, double-blind, placebo-controlled study to assess the safety and efficacy of 1% D-3-hydroxybutyrate eye drops in patients with dry eye disease. A total of 65 patients were randomly assigned to either the placebo group or the 1% D-3-hydroxybutyrate group, and the treatments were administered 6 times a day for 4 weeks. We then evaluated corneal fluorescein staining, corneal and conjunctival rose Bengal staining, tear film break-up time (BUT), Schirmer score, and subjective symptoms. At both 2 and 4 weeks, the corneal rose Bengal score was significantly better in the 1% D-3-hydroxybutyrate group than in the placebo group. Among patients with an initial Schirmer score of ≤5 mm, the corneal fluorescein staining score was significantly better in the 1% D-3-hydroxybutyrate group than in the placebo group at two weeks. Mild ocular symptoms occurred in both groups, and these spontaneously resolved. The present study suggested that 1% D-3-hydroxybutyrate eye drops are safe and effective in treating ocular surface disorders in patients with tear-deficient dry eye disease.

Original languageEnglish
Article number20855
JournalScientific Reports
Volume6
DOIs
Publication statusPublished - 2016 Feb 11

Fingerprint

3-Hydroxybutyric Acid
Eye Diseases
Ophthalmic Solutions
Double-Blind Method
Safety
Placebos
Rose Bengal
Staining and Labeling
Fluorescein
Tears

ASJC Scopus subject areas

  • General

Cite this

Randomized, Multicenter, Double-Blind Study of the Safety and Efficacy of 1%D-3-Hydroxybutyrate eye drops for Dry Eye Disease. / Kawakita, Tetsuya; Uchino, Miki; Fukagawa, Kazumi; Yoshino, Kenichi; Shimazaki, Seika; Toda, Ikuko; Tanaka, Mari; Arai, Hiroyuki; Sakatani, Keiko; Hata, Seiichiro; Okano, Takashi; Tsubota, Kazuo.

In: Scientific Reports, Vol. 6, 20855, 11.02.2016.

Research output: Contribution to journalArticle

Kawakita, T, Uchino, M, Fukagawa, K, Yoshino, K, Shimazaki, S, Toda, I, Tanaka, M, Arai, H, Sakatani, K, Hata, S, Okano, T & Tsubota, K 2016, 'Randomized, Multicenter, Double-Blind Study of the Safety and Efficacy of 1%D-3-Hydroxybutyrate eye drops for Dry Eye Disease', Scientific Reports, vol. 6, 20855. https://doi.org/10.1038/srep20855
Kawakita, Tetsuya ; Uchino, Miki ; Fukagawa, Kazumi ; Yoshino, Kenichi ; Shimazaki, Seika ; Toda, Ikuko ; Tanaka, Mari ; Arai, Hiroyuki ; Sakatani, Keiko ; Hata, Seiichiro ; Okano, Takashi ; Tsubota, Kazuo. / Randomized, Multicenter, Double-Blind Study of the Safety and Efficacy of 1%D-3-Hydroxybutyrate eye drops for Dry Eye Disease. In: Scientific Reports. 2016 ; Vol. 6.
@article{94389f55a44548a29cf8aaa079179b11,
title = "Randomized, Multicenter, Double-Blind Study of the Safety and Efficacy of 1{\%}D-3-Hydroxybutyrate eye drops for Dry Eye Disease",
abstract = "In a previous study, we demonstrated that topical D-beta-hydroxybutyrate ameliorates corneal epithelial erosion and superficial punctate keratopathy in a rat model of dry eye disease. In the current investigation, we performed a prospective, randomized, multicentre, double-blind, placebo-controlled study to assess the safety and efficacy of 1{\%} D-3-hydroxybutyrate eye drops in patients with dry eye disease. A total of 65 patients were randomly assigned to either the placebo group or the 1{\%} D-3-hydroxybutyrate group, and the treatments were administered 6 times a day for 4 weeks. We then evaluated corneal fluorescein staining, corneal and conjunctival rose Bengal staining, tear film break-up time (BUT), Schirmer score, and subjective symptoms. At both 2 and 4 weeks, the corneal rose Bengal score was significantly better in the 1{\%} D-3-hydroxybutyrate group than in the placebo group. Among patients with an initial Schirmer score of ≤5 mm, the corneal fluorescein staining score was significantly better in the 1{\%} D-3-hydroxybutyrate group than in the placebo group at two weeks. Mild ocular symptoms occurred in both groups, and these spontaneously resolved. The present study suggested that 1{\%} D-3-hydroxybutyrate eye drops are safe and effective in treating ocular surface disorders in patients with tear-deficient dry eye disease.",
author = "Tetsuya Kawakita and Miki Uchino and Kazumi Fukagawa and Kenichi Yoshino and Seika Shimazaki and Ikuko Toda and Mari Tanaka and Hiroyuki Arai and Keiko Sakatani and Seiichiro Hata and Takashi Okano and Kazuo Tsubota",
year = "2016",
month = "2",
day = "11",
doi = "10.1038/srep20855",
language = "English",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Randomized, Multicenter, Double-Blind Study of the Safety and Efficacy of 1%D-3-Hydroxybutyrate eye drops for Dry Eye Disease

AU - Kawakita, Tetsuya

AU - Uchino, Miki

AU - Fukagawa, Kazumi

AU - Yoshino, Kenichi

AU - Shimazaki, Seika

AU - Toda, Ikuko

AU - Tanaka, Mari

AU - Arai, Hiroyuki

AU - Sakatani, Keiko

AU - Hata, Seiichiro

AU - Okano, Takashi

AU - Tsubota, Kazuo

PY - 2016/2/11

Y1 - 2016/2/11

N2 - In a previous study, we demonstrated that topical D-beta-hydroxybutyrate ameliorates corneal epithelial erosion and superficial punctate keratopathy in a rat model of dry eye disease. In the current investigation, we performed a prospective, randomized, multicentre, double-blind, placebo-controlled study to assess the safety and efficacy of 1% D-3-hydroxybutyrate eye drops in patients with dry eye disease. A total of 65 patients were randomly assigned to either the placebo group or the 1% D-3-hydroxybutyrate group, and the treatments were administered 6 times a day for 4 weeks. We then evaluated corneal fluorescein staining, corneal and conjunctival rose Bengal staining, tear film break-up time (BUT), Schirmer score, and subjective symptoms. At both 2 and 4 weeks, the corneal rose Bengal score was significantly better in the 1% D-3-hydroxybutyrate group than in the placebo group. Among patients with an initial Schirmer score of ≤5 mm, the corneal fluorescein staining score was significantly better in the 1% D-3-hydroxybutyrate group than in the placebo group at two weeks. Mild ocular symptoms occurred in both groups, and these spontaneously resolved. The present study suggested that 1% D-3-hydroxybutyrate eye drops are safe and effective in treating ocular surface disorders in patients with tear-deficient dry eye disease.

AB - In a previous study, we demonstrated that topical D-beta-hydroxybutyrate ameliorates corneal epithelial erosion and superficial punctate keratopathy in a rat model of dry eye disease. In the current investigation, we performed a prospective, randomized, multicentre, double-blind, placebo-controlled study to assess the safety and efficacy of 1% D-3-hydroxybutyrate eye drops in patients with dry eye disease. A total of 65 patients were randomly assigned to either the placebo group or the 1% D-3-hydroxybutyrate group, and the treatments were administered 6 times a day for 4 weeks. We then evaluated corneal fluorescein staining, corneal and conjunctival rose Bengal staining, tear film break-up time (BUT), Schirmer score, and subjective symptoms. At both 2 and 4 weeks, the corneal rose Bengal score was significantly better in the 1% D-3-hydroxybutyrate group than in the placebo group. Among patients with an initial Schirmer score of ≤5 mm, the corneal fluorescein staining score was significantly better in the 1% D-3-hydroxybutyrate group than in the placebo group at two weeks. Mild ocular symptoms occurred in both groups, and these spontaneously resolved. The present study suggested that 1% D-3-hydroxybutyrate eye drops are safe and effective in treating ocular surface disorders in patients with tear-deficient dry eye disease.

UR - http://www.scopus.com/inward/record.url?scp=84958567824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958567824&partnerID=8YFLogxK

U2 - 10.1038/srep20855

DO - 10.1038/srep20855

M3 - Article

C2 - 26865350

AN - SCOPUS:84958567824

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 20855

ER -